IL243189A0 - Use of nk-1 receptor antagonist serlopitant in pruritus - Google Patents

Use of nk-1 receptor antagonist serlopitant in pruritus

Info

Publication number
IL243189A0
IL243189A0 IL243189A IL24318915A IL243189A0 IL 243189 A0 IL243189 A0 IL 243189A0 IL 243189 A IL243189 A IL 243189A IL 24318915 A IL24318915 A IL 24318915A IL 243189 A0 IL243189 A0 IL 243189A0
Authority
IL
Israel
Prior art keywords
serlopitant
pruritus
receptor antagonist
antagonist
receptor
Prior art date
Application number
IL243189A
Other languages
Hebrew (he)
Inventor
Zhang Xiaoming
F Schnipper Edward
J Perlman Andrew
W Larrick James
Original Assignee
Menlo Therapeutics Inc
Zhang Xiaoming
F Schnipper Edward
J Perlman Andrew
W Larrick James
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc, Zhang Xiaoming, F Schnipper Edward, J Perlman Andrew, W Larrick James filed Critical Menlo Therapeutics Inc
Publication of IL243189A0 publication Critical patent/IL243189A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL243189A 2013-06-24 2015-12-17 Use of nk-1 receptor antagonist serlopitant in pruritus IL243189A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (1)

Publication Number Publication Date
IL243189A0 true IL243189A0 (en) 2016-02-29

Family

ID=51230173

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243189A IL243189A0 (en) 2013-06-24 2015-12-17 Use of nk-1 receptor antagonist serlopitant in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (en)
JP (2) JP2016523260A (en)
KR (1) KR20160023692A (en)
CN (1) CN105473138A (en)
AU (2) AU2014302694B2 (en)
BR (1) BR112015031724A2 (en)
CA (1) CA2915474A1 (en)
HK (1) HK1223820A1 (en)
IL (1) IL243189A0 (en)
MX (2) MX366728B (en)
PH (2) PH12015502777A1 (en)
RU (1) RU2666219C2 (en)
WO (1) WO2014209962A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6741655B2 (en) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Emulsion formulation of aprepitant
KR20230173743A (en) * 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. Method of Treatment with Tradipitant
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
AU2016391046A1 (en) * 2016-02-01 2018-08-16 Heron Therapeutics, Inc. Emulsion comprising an NK-1 receptor antagonist
KR20190039936A (en) * 2016-06-29 2019-04-16 멘로 쎄라퓨틱스 인크. Use of neurokinin-1 antagonists to treat various pruritic conditions
AU2018331267B2 (en) * 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2019088926A1 (en) * 2017-11-01 2019-05-09 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
WO2019152232A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CN115015440A (en) * 2022-07-08 2022-09-06 江苏杜瑞制药有限公司 Method for detecting naftifine in biological sample
CN117503699A (en) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 Aprepitant oral liquid preparation and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (en) * 2004-01-27 2010-01-20 默克公司 Hydroisoindoline tachykinin receptor antagonists
AR047439A1 (en) * 2004-01-27 2006-01-18 Merck & Co Inc TAQUIQUININE HYDROISOINDOLINE RECEIVER ANTAGONISTS
WO2007008564A1 (en) 2005-07-11 2007-01-18 Merck & Co., Inc. Process for making hydroisoindoline tachykinin receptor antagonists
AU2006302562A1 (en) 2005-10-04 2007-04-19 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
US20100209496A1 (en) 2006-09-06 2010-08-19 Eleni Dokou Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2008054690A2 (en) 2006-11-02 2008-05-08 Merck & Co., Inc. Polymorphs of a hydroisoindoline tachykinin receptor antagonist
US20100113469A1 (en) 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (en) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Gel, possessing anti- inflammatory and antiallergic effect

Also Published As

Publication number Publication date
AU2020200259A1 (en) 2020-02-06
JP2019142960A (en) 2019-08-29
MX366728B (en) 2019-07-22
MX2019008643A (en) 2019-09-10
AU2014302694B2 (en) 2019-10-17
RU2666219C2 (en) 2018-09-06
BR112015031724A2 (en) 2017-07-25
PH12020500255A1 (en) 2021-02-22
RU2015154037A (en) 2017-07-28
EP3013336A1 (en) 2016-05-04
PH12015502777A1 (en) 2016-03-21
CA2915474A1 (en) 2014-12-31
HK1223820A1 (en) 2017-08-11
MX2015017763A (en) 2016-06-21
JP2016523260A (en) 2016-08-08
KR20160023692A (en) 2016-03-03
CN105473138A (en) 2016-04-06
AU2014302694A1 (en) 2016-01-07
WO2014209962A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
HUS2200048I1 (en) Fcrn antagonists and methods of use
HK1223820A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus nk-1
HK1218625A1 (en) Chimeric antigen receptor and methods of use thereof
IL243459B (en) Targeting of cytokine antagonists
PL2970473T3 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EP2945630A4 (en) 4-fluoropiperidine orexin receptor antagonists
EP2964226A4 (en) 2-pyridyloxy-4-ether orexin receptor antagonists
GB201305668D0 (en) Avs6 Integrin Antagonists
EP3020707A4 (en) P2x4 receptor antagonist
PL2945963T3 (en) Peptide inhibitors of nicotinic acetylcholine receptor
HRP20190141T1 (en) Progesterone receptor antagonist dosage form
IL246091A0 (en) Opioid antagonist formulations
EP3010540A4 (en) Use of il-20 antagonists for alleviating obesity
TH1501007504A (en) Use of serlopitant, which is NK-1 Receptor antagonists in pruritus
GB201304666D0 (en) Dopamine receptor antagonist